Finance

Lists
ZBIO:NASDAQ
Zenas Biopharma Inc
25,30 $
+1,79%
(+0,44) 1D
15 հոկ, 09:30:13 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ZBIO...
Open
24,96 $
High
25,30 $
Low
24,96 $
Mkt. cap
1,65 մլրդ
Avg. vol.
682,40 հզր
Volume
108,00
52-wk high
44,60 $
52-wk low
13,50 $
EPS
-8,97 $
Shares outstanding
65,18 մլն
No. of employees
167
Open
24,96 $
High
25,30 $
Low
24,96 $
Mkt. cap
1,65 մլրդ
Avg. vol.
682,40 հզր
Volume
108,00
52-wk high
44,60 $
52-wk low
13,50 $
EPS
-8,97 $
Shares outstanding
65,18 մլն
No. of employees
167
News stories
From web sources and news partners
About Zenas Biopharma Inc
CEO-
Employees167
Founded2019
HeadquartersՈւոլթեմ, Մասսաչուսեթս, Միացյալ Նահանգներ
Sector-
Analyst ratings
Based on 5 analysts giving stock ratings to ZBIO in the past 3 months
Strong buy
Buy
4
Hold
1
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for ZBIO in the last 3 months.
Highest
Current 25,30 $
55,00 $ (+117,35%)
Average
44,80 $ (+77,04%)
Lowest
32,00 $ (+26,46%)
Analyst
Recommendation
Action
Price target
Projected
Date
Unknown Analyst
Wedbush
Buy
Maintained
45,00 $
+77,8%
10/13/2026
Matthew Caufield
H.C. Wainwright
Buy
Reiterated
44,00 $
+73,9%
10/13/2026
Yigal Nochomovitz
Citi
Buy
Maintained
48,00 $
+89,7%
10/12/2026
Martin Fan
Wedbush
Buy
Maintained
45,00 $
+77,8%
09/30/2026
Judah Frommer
Morgan Stanley
Hold
Maintained
32,00 $
+26,5%
08/17/2026
David Nierengarten
Wedbush
Buy
Maintained
45,00 $
+77,8%
08/14/2026
Yatin Suneja
Guggenheim
Buy
Reiterated
55,00 $
+117,3%
08/13/2026
Patrick Trucchio
H.C. Wainwright
Buy
Reiterated
44,00 $
+73,9%
06/08/2026
Cory Kasimov
Evercore ISI
Buy
Maintained
55,00 $
+117,3%
03/17/2026
Last report
13 օգս, 2026 թ.
Fiscal period
Q2 2026
-1,77 $ / -0,75 $
-134,44%miss
Revenue / Est. (USD)
1,00 մլն / 15,00 մլն
-93,33%miss
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025 թ. սեպ
2025 թ. դեկ
2026 թ. մրտ
2026 թ. հնս
Revenue
-
-
-
1,00 մլն
Cost of goods sold
34,40 մլն
55,72 մլն
60,44 մլն
62,91 մլն
Cost of revenue
34,40 մլն
55,72 մլն
60,44 մլն
62,91 մլն
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
13,18 մլն
15,59 մլն
16,91 մլն
15,75 մլն
Operating expense
13,18 մլն
15,59 մլն
16,91 մլն
15,75 մլն
Total operating expenses
47,58 մլն
71,31 մլն
77,35 մլն
78,66 մլն
Operating income
-47,58 մլն
-71,31 մլն
-77,35 մլն
-77,66 մլն
Other non operating income
1,08 մլն
-7,48 մլն
-24,00 հզր
16,00 հզր
EBT including unusual items
-51,50 մլն
-240,34 մլն
-80,99 մլն
-111,34 մլն
EBT excluding unusual items
-46,50 մլն
-73,66 մլն
-80,99 մլն
-81,34 մլն
Income tax expense
-
106,00 հզր
-
114,00 հզր
Effective tax rate
-
-0,04%
-
-0,10%
Other operating expenses
-
-
-
-
Net income
-51,50 մլն
-240,44 մլն
-80,99 մլն
-111,46 մլն
Net profit margin
-
-
-
-11 145,60%
Earnings per share
-1,22
-1,39
-1,46
-1,77
Interest and investment income
-
12,15 մլն
3,02 մլն
6,60 մլն
Interest expense
-
-7,33 մլն
-6,63 մլն
-10,30 մլն
Net interest expenses
-
4,82 մլն
-3,61 մլն
-3,70 մլն
Depreciation and amortization charges
-
-
-
-
EBITDA
-47,57 մլն
-71,30 մլն
-77,34 մլն
-77,66 մլն
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google Apps